RT Journal Article
SR Electronic
T1 Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP S2
OP S9
DO 10.1212/WNL.49.1_Suppl_1.S2
VO 49
IS 1 Suppl 1
A1 Matthew B. Stern
YR 1997
UL http://n.neurology.org/content/49/1_Suppl_1/S2.abstract
AB A number of unresolved issues complicate the effective management of patients with Parkinson's disease (PD). Chief among these is the role of neuroprotective versus symptomatic pharmacologic interventions. Until the etiology of PD is further defined, consensus on appropriate management of this illness is unlikely. Clinicians may best serve their patients by taking a pragmatic approach to the treatment of PD that utilizes potentially beneficial interventions in eligible patients. Such an approach would incorporate possible neuroprotective (e.g., selegiline, dopamine agonists, sustained-release levodopa) and dopamine-sparing (e.g., combination levodopa/dopamine agonist therapy) strategies whenever possible while retaining adequate symptomatic control.